Artiva Biotherapeutics, Inc.

NASDAQ:ARTV

Biotechnology

Healthcare
$3.77 -3.37%

-$0.34 today

Market cap
$186.36M
Beta
2.40
P/E (TTM)
-2.7
EPS (TTM)
-$3.53
52W Low $1.47High $14.53

Volume 0.97M

Average 0.48M

ARTV Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Artiva Biotherapeutics, Inc.NASDAQ: ARTV

Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026

Selling, general & admin dips below year-ago levels

Q1 FY2026 selling, general & admin of $5.12M fell 0.0% year over year, behind the +8.2% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 3.6% from the prior quarter. Over 3 fiscal years it compounded at -0.8% a year.

Context

  • Selling, general & admin increased in 2 of the last 3 fiscal years.

What to watch

Whether selling, general & admin reaches the consensus estimate of $0 (-100.0%) for the fiscal year ending Dec 2026, a slowdown from the +17.8% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$5.12M+3.6% QoQ
Last fiscal yearDec 2025
$20.27M+17.8% YoY
LTMMar 2026
$20.27M+8.2% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-0.0%-100.0%-100.0 pp
1 year+17.8%-100.0%-117.8 pp
3-year CAGR-0.8%+10.1%+11.0 pp
5-year CAGR+139.8%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
20.27M USD
Year-over-year change
+17.8%
4-year CAGR
+12.0%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How ARTV compares with its peers on the latest reported figures

  • Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +8.2% is the highest of 8, against a peer median of -23.4%.
  • Over three fiscal years its annual growth of -0.8% compares with a peer median of -5.3%.
ARTV Competitors
Selling, General & Admin for ARTV and competitors
Company Period LTM YoY 3-year CAGR% of revenue
STROSutro Biopharma, Inc.LTM Mar 2026$35.33M USD-27.9%-11.7%35.5%
ZNTLZentalis Pharmaceuticals, Inc.LTM Mar 2026$34.97M USD-57.3%-11.6%—
DTILPrecision BioSciences, Inc.LTM Mar 2026$30.49M USD-13.9%-7.9%67.6%
ALXOALX Oncology Holdings Inc.LTM Mar 2026$21.28M USD-23.4%-6.3%—
CNTBConnect Biopharma Holdings LimitedFY2025$20.34M USD+5.8%-0.8%31781.3%
ARTVArtiva Biotherapeutics, Inc.LTM Mar 2026$20.27M USD+8.2%-0.8%—
STTKShattuck Labs, Inc.LTM Mar 2026$17.37M USD-6.9%-4.3%1736.5%
GUTSFractyl Health, Inc. Common StockLTM Mar 2026$17.25M USD—+15.2%—
IFRXInflaRx N.V.LTM Mar 2026€14.24M EUR-27.6%+7.0%48538.7%
Peer median (excluding ARTV) —-23.4%-5.3%1736.5%

Competitors are the stored peer set for ARTV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue2M4.93M33.49M251K0
Cost of Revenue00002.6M
Gross Profit2M4.93M33.49M251K(2.6M)
Gross Margin100.0%100.0%100.0%100.0%—
Research & Development42.41M43.98M50.25M50.33M69.54M
Selling, General & Admin12.86M20.78M13.91M17.21M20.27M
Operating Expenses55.27M64.76M64.16M67.53M88.01M
Depreciation & Amortization248K1.16M2.27M2.43M2.6M
EBITDA(71.58M)(57.18M)(25.36M)(56.06M)(81.27M)
EBITDA Margin-3575.3%-1159.5%-75.7%-22335.5%—
Operating Income(53.27M)(59.83M)(30.67M)(67.28M)(90.61M)
Operating Margin-2660.9%-1213.3%-91.6%-26805.6%—
Interest Income01.29M2.54M5.35M5.96M
Interest Expense00000
Other Income / Expenses(18.55M)1.49M3.05M8.79M6.75M
Income Before Tax(71.83M)(58.34M)(27.62M)(58.49M)(83.87M)
Pre-Tax Margin-3587.7%-1183.0%-82.5%-23304.0%—
Income Tax Expense053K72K00
Net Income(71.83M)(58.39M)(27.7M)(58.49M)(83.87M)
Net Margin-3587.7%-1184.1%-82.7%-23304.0%—
EPS (Basic)(4.08)(3.32)(1.19)(5.20)(3.43)
EPS (Diluted)(4.08)(3.32)(1.19)(5.20)(3.43)
Weighted Avg Shares17.58M17.58M23.28M24.36M24.44M
Weighted Avg Shares (Diluted)17.58M17.58M23.28M24.36M24.44M

Artiva Biotherapeutics, Inc.

NASDAQ:ARTV

Intrinsic Alpha fair value

Locked

Current Price

$3.77

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.